Research programme: LMA targeting bispecific antibody therapeutics - HaemaLogiX
Alternative Names: Lambda bispecific - HaemaLogiXLatest Information Update: 28 Apr 2023
At a glance
- Originator HaemaLogiX
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Multiple myeloma
Most Recent Events
- 19 Apr 2023 Early research in Multiple myeloma in Australia (Parenteral), prior to April 2023 (HaemaLogix pipeline, April 2023)